Healthy controls (n = 15) | Spondylarthropathies (n = 32) | Rheumatoid arthritis (n = 22) | P | |
---|---|---|---|---|
CD3+ T cells (/mm 3 ) | 1397 ± 79 (925 to 1806) | 1360 ± 80.8 (622 to 2681) | 1129 ± 140 (336 to 3024) | 0.005 (KW) RA vs HC 0.004 (MW) SpA vs HC NS SpA vs RA 0.007 (MW) |
CD4+ T cells (/mm 3 ) | 817 ± 45 (449 to 1024) | 875 ± 49.5 (391 to 1699) | 804 ± 102 (239 to 2306) | NS |
CD8+ T cells (/mm 3 ) | 573 ± 47 (379 to 860) | 457 ± 39.6 (130 to 979) | 326 ± 52 (72 to 1260) | 0.0006 (KW) RA vs HC 0.0007 (MW) SpA vs HC 0.051 RA vs SpA 0.006 (MW) |
HLA-DR+ Foxp3- CD4+ T cells (% of CD4+ T cells) | 16.6 ± 5.53 (5 to 70) | 22.03 ± 4.56 (4 to 100) | 12.14 ± 1.29 (5 to 26) | NS |
CD25+ Foxp3+ CD4+ T cells (% of CD4+T cells) | 7.94 ± 1.04 (3.6 to 16) | 8.2 ± 0.61 (4 to 14.4) | 8.72 ± 0.7 (2.9 to 13.5) | NS |
Intracellular CTLA-4 in CD4+ T cells (%) | 4.35 ± 1.10 (1 to 13.3) | 2.51 ± 0.40 (0 to 5.9) | 1.35 ± 0.48*,§ (0 to 7.5) | 0.005 (KW) RA vs HC 0.003 SpA vs HC NS RA vs SpA 0.02 |
Intracellular CTLA-4 in CD4+ Treg (%) | 2.76 ± 0.44 (0.5 to 6.3) | 1.88 ± 0.34 (0 to 5) | 0.90 ± 0.32*,§ (0 to 3.9) | 0.007 (KW) RA vs HC 0.0045 SpA vs HC NS SpA vs RA 0.027 |
Intracellular CTLA-4 in Activated CD4+ T cells (%) | 1.59 ± 0.72 (0 to 7) | 0.63 ± 0.26 (0 to 5) | 0.5 ± 0.29 (0 to 5) | NS |
Intracellular CTLA-4 in CD8+ T cells (%) | 2.03 ± 0.57 (0.4 to 7) | 2.64 ± 0.32 (0 to 6.3) | 3.49 ± 0.88 (0.1 to 13.7) | NS |
Intracellular CTLA-4 in CD3- lymphocytes (%) | 0.89 ± 0.72 (0 to 8) | 0.67 ± 0.21 (0 to 3.3) | 3.50 ± 0.77*,§ (0 to 11) | 0.0025 (KW) RA vs HC 0.0077 SpA vs HC NS SpA vs RA: 0.0017 |
Intracellular CTLA-4 in the lymphocyte gate (total lymphocytes) (%) | 7.27 ± 1.27 (1.4 to 15) | 3 ± 0.48 (0 to 7.6) | 6.89 ± 1.3§ (0.1 to 19.3) | 0.004 (KW) RA vs HC 0.0045 SpA vs HC NS SpA vs RA 0.007 |